FDA grants priority review for iberdomide-based myeloma regimen
1. The FDA has granted priority review for iberdomide, a first-in-class oral CELMoD designed to degrade transcription factors more effectively ...
1. The FDA has granted priority review for iberdomide, a first-in-class oral CELMoD designed to degrade transcription factors more effectively ...
1. The Stealth AXiS™ system has received regulatory clearance as the first platform to natively unify AI-driven planning and robotic ...
1. Yartemlea (narsoplimab-wuug) is the first on‑label complement inhibitor for hematopoietic stem cell transplant (HSCT) associated thrombotic microangiopathy, associated with improvements ...
1. New FDA communication introduces a more flexible, risk‑based chemistry, manufacturing, and controls (CMC) framework for cell and gene therapies, ...
1. Nuzolvence (zoliflodacin) is the first single‑dose oral agent for uncomplicated urogenital gonorrhea, showing non‑inferior cure rates to ceftriaxone‑based therapy ...
Oral gonorrhea antibiotic Nuzolvence approved just weeks ago The Food and Drug Administration recently approved Nuzolvence (zoliflodacin) as a first‑in‑class ...
Amryta’s Sodesta gene therapy gains accelerated approval for ALS The Food and Drug Administration has granted accelerated approval to Sodesta, ...
1. The FDA has cleared the first Alzheimer’s blood test for community use, marking a pivotal step toward earlier and ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. FDA ...
The Scan by 2 Minute Medicine® is a pop-culture medical newsletter and exclusive benefit for 2 Minute Medicine Plus subscribers. Leucovorin ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.